Flt4 - FMS-like tyrosine kinase 4 Gene

Mus musculus

Also known as Chy; Flt-4; VEGFR3; VEGFR-3

Gene ID: 14257 | Gene type: protein coding

About Flt4

Chromosome 11: 49,500,090-49,543,566 forward strand.GRCm39:CM001004.3

This gene has 2 transcripts (splice variants), 196 orthologues, 53 paralogues and is associated with 27 phenotypes. Broad expression in lung adult (RPKM 14.6), ovary adult (RPKM 1.5) and 23 other tissues.

Summary

Enables vascular endothelial growth factor-activated receptor activity. Involved in lymphangiogenesis; regulation of blood vessel remodeling; and sprouting angiogenesis. Acts upstream of or within lung alveolus development; positive regulation of cell population proliferation; and respiratory system process. Predicted to be located in cytosol; nucleoplasm; and plasma membrane. Predicted to be part of receptor complex. Predicted to be integral component of plasma membrane. Is expressed in several structures, including alimentary system; branchial arch; cardiovascular system; central nervous system; and extraembryonic component. Used to study hereditary lymphedema. Human ortholog(s) of this gene implicated in hereditary lymphedema IA. Orthologous to human FLT4 (fms related receptor tyrosine kinase 4). [provided by Alliance of Genome Resources, Apr 2022]

Flt4 Products(1)

mRNA	Protein	Name
NM_008029.3	NP_032055.1	vascular endothelial growth factor receptor 3 precursor

Gene Ontology

Molecular Function
Biological Process

Molecular Function GO Annotation	Evidence	Reference	Source
enables protein binding	IPI IPI: Inferred from physical interaction	9247316	MGI
enables vascular endothelial growth factor receptor activity	IGI IGI: Inferred from genetic interaction	9247316	MGI

Biological Process GO Annotation	Evidence	Reference	Source
involved in blood vessel morphogenesis	IMP IMP: Inferred from mutant phenotype	9794766	MGI
acts upstream of or within lung alveolus development	IMP IMP: Inferred from mutant phenotype	24733830	MGI
acts upstream of or within lymph vessel development	IGI IGI: Inferred from genetic interaction	20439428	MGI
involved in lymph vessel development	IMP IMP: Inferred from mutant phenotype	19903896	MGI
involved in lymphangiogenesis	IMP IMP: Inferred from mutant phenotype	20697430	MGI
acts upstream of or within positive regulation of cell population proliferation	IGI IGI: Inferred from genetic interaction	9247316	MGI
involved in regulation of blood vessel remodeling	IMP IMP: Inferred from mutant phenotype	9794766	MGI
acts upstream of or within respiratory gaseous exchange by respiratory system	IMP IMP: Inferred from mutant phenotype	24733830	MGI
acts upstream of or within respiratory system process	IMP IMP: Inferred from mutant phenotype	24733830	MGI
involved in sprouting angiogenesis	IMP IMP: Inferred from mutant phenotype	18594512	MGI
involved in vasculature development	IMP IMP: Inferred from mutant phenotype	9794766	MGI

EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

Flt4 Protein Structure

IgI_VEGFR

IG_like

VEGFR-2_TMD

PKc_like

0
300
600
900
1200
1363 a.a.

Protein Preferred Names

Protein Names

vascular endothelial growth factor receptor 3

chylous ascites	receptor protein tyrosine kinase
tyrosine-protein kinase receptor FLT4

Recombinant Flt4 Proteins

Cat. No.	Product Name	Accession	Purity
HY-P74466	VEGFR-3/FLT4 Protein, Mouse (HEK293, His)	P35917 (Y25-E775)	≥95%
HY-P74467	VEGFR-3/FLT4 Protein, Mouse (HEK293, hFc)	P35917 (Y25-E775)	≥95%

Related Agents

Approval

Bioactive Molecules (3)

Cat. No.	Product Name	Purity	Rare Diseases
HY-10260	Vandetanib	99.95%	Yes
HY-10260B	Vandetanib hydrochloride	/	Unkown
HY-10260A	Vandetanib trifluoroacetate	/	Unkown

Clinical Phase

Bioactive Molecules (8)

Cat. No.	Product Name	Effect	Purity	Phase
HY-10205	Cediranib		99.58%	Phase 3
HY-100019	Rogaratinib	Inhibitor	99.86%	Phase 3
HY-13314	Tesevatinib	Inhibitor	99.21%	Phase 3
HY-13049	Cediranib maleate		99.95%	Phase 3
HY-110272	Vatalanib succinate	Inhibitor	/	Phase 3
HY-13034	Gandotinib	Inhibitor	99.82%	Phase 2
HY-10987A	ENMD-2076		99.12%	Phase 2
HY-10987	ENMD-2076 Tartrate		99.42%	Phase 2

Pre-clinical Phase

Bioactive Molecules (13)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-116624	MAZ51		99.96%	Unkown
HY-119933	RIPK1-IN-7	Inhibitor	98.56%	Unkown
HY-145293	TNIK-IN-3	Inhibitor	99.88%	Unkown
HY-15813	FIIN-1	Inhibitor	99.11%	Unkown
HY-10260S	Vandetanib-d6		/	Unkown
HY-10260S1	Vandetanib-d4		/	Unkown
HY-10260S2	Vandetanib-13C6		/	Unkown
HY-155178	Antiproliferative agent-34	Inhibitor	/	Unkown
HY-168114	Multi-kinase inhibitor 3	Inhibitor	/	Unkown
HY-168115	Multi-kinase inhibitor 4	Inhibitor	/	Unkown
HY-RS04994	FLT4 Human Pre-designed siRNA Set A	Pre-designed Sets	/	Unkown
HY-RS04995	Flt4 Mouse Pre-designed siRNA Set A	Pre-designed Sets	/	Unkown
HY-RS04996	Flt4 Rat Pre-designed siRNA Set A	Pre-designed Sets	/	Unkown

Orthologs Information

Species	Symbol	Source	ID
Homo sapiens	Flt4	NCBI	NCBI:2324
Rattus norvegicus	Flt4	NCBI	NCBI:114110

Name
Email *

	Sorry, but the email address you supplied was invalid.